First day of trading completed – now we’re continuing in Stockholm

CombiGenes vd, Jan Nilsson, drar igång 2017 med deltagande dels på två aktiedagar i Aktiespararnas regi i Lund och Stockholm dels på Aktietorget i Stockholm.
Se presentationen från Lund via länk nedan.

Aktietorget i Stockholm, 9 februari
Mäster Samuelsgatan 42, plan 3
Mellan kl.12.00 – 13.15 med enklare förtäring
Anmälan: inbjudan@aktietorget.se

Aktiedagen i Stockholm, 13 februari
Aktiespararna i Stockholm
Lokal: Café Opera
Mellan kl. 17.30 – 18.00

Aktiedagen i Lund, 31 januari
Se CombiGenes presentation här: https://youtu.be/pFE5PEICJfg

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Medicon Village, SE-223-81 Lund

 

Linked In     Twitter      Facebook